Fig. 2: HMMR is clinically significant in prostate cancer. | British Journal of Cancer

Fig. 2: HMMR is clinically significant in prostate cancer.

From: Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer

Fig. 2

Association between HMMR expression levels with an AR signalling signature (a) or acquired ADT resistance signature (b) from TCGA primary prostate cancer expression data. Scatter plot of the Spearman correlation analysis between HMMR expression and signature genes, where each symbol represents one patient. c Violin plot of HMMR protein expression in benign prostate tissues versus primary and metastatic castrate-resistant prostate cancer tissues. Plots show minimum and maximum values (lower and upper lines respectively). Data were analysed using one-way ANOVA with Tukey’s multiple comparison test (**p < 0.01). d–f HMMR mRNA expression is associated with shorter relapse-free survival in the TCGA (primary prostate cancer) and MSKCC (primary and metastatic CRPC) cohorts, and shorter overall survival rates in the SU2C (metastatic CRPC) cohort.

Back to article page